Uppsala, Sweden

Slavica Brnjic

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2018

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Slavica Brnjic

Introduction

Slavica Brnjic is a notable inventor based in Uppsala, Sweden. She has made significant contributions to the field of biochemistry, particularly in the area of proteasome research. Her work focuses on developing methods to screen compounds that can inhibit specific enzymes, which has implications for various therapeutic applications.

Latest Patents

Slavica Brnjic holds a patent for a method titled "Protease deubiquitinating inhibitor screening." This innovative method involves screening a compound to determine whether it acts as a proteasome deubiquitinating inhibitor of high specificity. The process includes contacting the compound with human 19S regulatory particles of the 26S proteasome and assessing its ability to inhibit the activity of deubiquitinating enzymes UCHL5 and USP14. A successful inhibition of these enzymes indicates that the compound is a highly specific proteasome deubiquitinating inhibitor. She has 1 patent to her name.

Career Highlights

Throughout her career, Slavica has demonstrated a commitment to advancing scientific knowledge and innovation. Her work has been recognized within the scientific community, and she continues to contribute to research that has the potential to impact therapeutic strategies.

Collaborations

Slavica Brnjic has collaborated with esteemed colleagues, including Padraig D'Arcy and Rolf Larsson. These partnerships have fostered a collaborative environment that enhances the research and development of innovative solutions in her field.

Conclusion

Slavica Brnjic's contributions to the field of biochemistry, particularly through her patent on proteasome deubiquitinating inhibitors, highlight her role as an influential inventor. Her work not only advances scientific understanding but also opens new avenues for therapeutic development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…